Europe biomarkers Market worth $28.11 billion by 2030
The report "Europe biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research)-Forecast to 2030" is projected to grow from USD 17.46 billion in 2025 and to reach USD 28.11 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 10.0% during the forecast period.
Browse 120 market data Tables and 80 Figures spread through 150 Pages and in-depth TOC on "Europe biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research)-Forecast to 2030
View detailed Table of Content here -https://www.marketsandmarkets.com/Market-Reports/europe-biomarkers-market-57574673.html
The Europe biomarkers market is growing, driven by several key factors, including the rising burden of chronic and age-related diseases and a strong focus on precision and personalized medicine across Europe.
The safety biomarkers segment accounted for the largest share by type in the Europe biomarkers market in 2024.
The Europe biomarkers market is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further divided into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, safety biomarkers accounted for the largest share of the Europe biomarkers market. This dominance is driven by their widespread adoption in drug development to assess toxicity and identify potential adverse effects early. Regulatory authorities in Europe increasingly require the use of safety biomarkers to ensure candidate drugs meet safety standards before advancing to later clinical phases. Additionally, pharmaceutical companies are investing in safety biomarker strategies to reduce late-stage clinical failures and support better decision-making during preclinical and early clinical trials.
In 2024, the NGS segment is expected to be the fastest-growing in the Europe biomarkers market, by application.
The Europe biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR is estimated to register the highest CAGR during the forecast period of 2025-2030, outpacing immunoassays and other technologies. The need for high-throughput drives it, multiplex analysis of genomic biomarkers in oncology and rare-disease programs, where a single NGS run can capture hundreds of variants and complex signatures that older methods cannot easily resolve.
The UK accounted for the largest regional share in the Europe biomarkers market in 2024.
The Europe biomarkers market is divided mainly among Germany, the UK, France, Italy, Spain, and the rest of Europe. The UK is expected to be one of the fastest-growing national markets for biomarkers, supported by strong precision medicine policies, a large NHS genomics and cancer network, and early adoption of advanced diagnostic platforms. The expanding use of genomic and protein biomarkers in national screening programs, real-world evidence studies, and innovative payment models is accelerating demand, positioning the UK as a key engine of biomarker growth in the region.
Key players in the Europe biomarkers market include F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), QIAGEN (Germany), Eurofins Scientific (Luxembourg), bioMérieux (France), R-Biopharm AG (Germany), Synexa Life Sciences BV (Netherlands), Proteome Sciences (UK)
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
